Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT ID: NCT01581593

Last Updated: 2021-02-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-12
• Study Completion Date: 2014-08-27

Brief Summary

The purpose of this study is to determine whether Kedrion IVIG 10% (an immunoglobulin solution) is effective in treating Primary Immunodeficiency (PID).

Detailed Description

People with primary immunodeficiency diseases (PID) have a defective immune system and experience recurrent protozoal, bacterial, fungal and viral infections. Antibody deficiencies make up the largest group of PIDs.

The standard care for patients with PID is replacement immunoglobulin (a class of antibodies) solution. Prophylactic treatment with intravenous immunoglobulin (IVIG) solution has been shown to increase the time free from serious infection.

Kedrion IVIG 10% is a new preparation of an immunoglobulin G (IgG) solution. Kedrion IVIG 10% will be given by IV infusion to all study participants. The data collected will help determine whether Kedrion IVIG 10% is suitable for treating PID subjects.

Conditions

Primary Immunodeficiency; Agammaglobulinemia; Hypogammaglobulinemia; Antibody Deficiency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Kedrion IVIG 10%

Kedrion IVIG 10% treatment.

Group Type: EXPERIMENTAL

Kedrion IVIG 10%

Intervention Type: BIOLOGICAL

Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months

Interventions

Kedrion IVIG 10%

Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Confirmed clinical diagnosis of a Primary Immunodeficiency Disease
• Male or female, ages 2 to 70 years
• Received 300-900 mg/kg of a licensed IVIG therapy at 21 or 28 day intervals for at least 3 months prior to this study
• 2 documented IgG trough levels of ≥ 5 g/L are obtained at two infusion cycles (21 or 28 days) within 12 months (one must be within 6 months) prior to study enrolment
• Non-pregnant females of child-bearing potential who agree to use adequate birth control during the study
• Subject is willing to comply with the protocol
• Authorization to access personal health information.
• Signed the informed consent form and a child assent form, if appropriate.

Exclusion Criteria

• If currently participating in a trial of SCIG can be enrolled if they are switched to IVIG for three infusion cycles (21 or 28 days) prior to enrolment in this study

• Has secondary immunodeficiency.
• Newly diagnosed and has not been treated with immunoglobulin or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency.
• Has a history of repeated reactions or hypersensitivity to IVIG or other injectable forms of IgG.
• Has a history of thrombotic events defined by at least 1 event in subject's lifetime.
• Has IgA deficiency and is known to have antibodies to IgA.
• Has received blood products other than human albumin or human immunoglobulin within 12 months prior to enrolment.
• Has significant protein losing enteropathy, nephrotic syndrome or lymphangiectasia.
• Has an acute infection as documented by culture or diagnostic imaging and/or a body temperature exceeding 38.5 °C (101.3 °F) within 7 days prior to screening
• Has a known history or is positive at enrolment for human immunodeficiency virus (HIV) type 1 by NAT, hepatitis B virus (HBsAg and NAT), hepatitis C virus (by NAT), or hepatitis A virus (by NAT).
• Has levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times of the upper limit of normal for the laboratory designated for the study.
• Has an implanted venous access device
• Has profound anemia or persistent severe neutropenia (≤ 1000 neutrophils per mm3)or lymphopenia of less than 500 cells per microliter.
• Has a severe chronic condition such as renal failure (creatinine concentration > 2.0 times the upper limit of normal) with proteinuria, congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g. atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity, or any other condition that the investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
• Has a history of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to enrolment.
• Has history of epilepsy or multiple episodes of migraine (defined as at least one episode within 6 months of enrolment) not completely controlled by medication.
• Is receiving steroids (oral or parenteral daily dose of ≥ 0.15 mg/kg/day of prednisone or equivalent) OR other immunosuppressive drugs or chemotherapy.
• Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
• Has participated in another clinical study within 3 weeks prior to study enrolment.

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kedrion S.p.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mirella Calcinai, MD

Role: STUDY_DIRECTOR

Kedrion SpA

Locations

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Allergy Associates of the Palm Beaches

North Palm Beach, Florida, United States

Family Allergy & Asthma Center, PC

Atlanta, Georgia, United States

Rush University

Chicago, Illinois, United States

University of Iowa Hospital and Clinics

Iowa City, Iowa, United States

Midwest Immunology Clinic

Plymouth, Minnesota, United States

AAIR Research Center

Rochester, New York, United States

Optimed Research, LTD

Columbus, Ohio, United States

Dallas Allergy Immunology Research

Dallas, Texas, United States

AARA Research Center

Dallas, Texas, United States

Virginia Commonwealth University Health Systems

Richmond, Virginia, United States

Marycliff Allergy Specialists

Spokane, Washington, United States

Gordon Sussman Clinical Research Inc.

Toronto, Ontario, Canada

Pediatric & Adult Allergy & Clinical Immunology

Toronto, Ontario, Canada

The Hospital for Sick Children

Toronto, Ontario, Canada

Countries

United States; Canada

Other Identifiers

KB052

Identifier Type: -

Identifier Source: org_study_id